Observational studyMedicine2026
Fasting glucose-to-HDL cholesterol ratio and risk of MASLD in nonobese Chinese adults: A retrospective cohort study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in nonobese individuals; however, reliable markers for early risk identification remain limited. The fasting glucose-to-high-density lipoprotein cholesterol (FHR) ratio, which reflects integrated glucolipid metabolism, has emerged as a potential indicator. This study aimed to evaluate the association between FHR and the incidence of MASLD in nonobese adults. This retrospective cohort study included 16,173 nonobese Chinese adults (body mass index < 25 kg/m2) from the Wenzhou Health Examination Cohort. Participants without MASLD at baseline were categorized into quartiles according to their FHR levels. Incident MASLD was diagnosed using abdominal ultrasonography during follow-up. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for demographic, clinical, and metabolic factors. Dose-response relationships were assessed using restricted cubic spline models, and receiver operating characteristic (ROC) analysis was performed to evaluate predictive performance. During follow-up, 2322 participants developed MASLD. Higher FHR levels were significantly associated with an increased risk of MASLD. In the fully adjusted model, each 1-unit increase in FHR was associated with a 22% higher risk of MASLD (HR, 1.22; 95% CI: 1.17-1.27, P < .001). Compared to the lowest quartile, the highest quartile showed a significantly elevated risk (HR: 2.10, 95% CI: 1.78-2.48; P for trend < 0.001). A positive dose-response relationship was also observed. ROC analysis showed that FHR had a moderate predictive ability (AUC, 0.701; 95% CI, 0.690 to 0.713), with an optimal cutoff value of 3.87. Elevated FHR was independently associated with an increased risk of MASLD in nonobese Chinese adults. Thus, FHR may serve as a simple and cost-effective biomarker for early risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.